Calcitonin gene-related peptide (CGRP) and the pathophysiology of headache: therapeutic implications.
Cerebral blood vessels are innervated by sensory nerves that store several neurotransmitters. In primary headaches, there is a clear association between head pain and the release of the neuropeptide calcitonin gene-related peptide (CGRP). Furthermore, when triptan antimigraine agents are administered, headache subsides and the neuropeptide release normalises, in part via a presynaptic effect. The central role of CGRP in primary headaches has led to the search for suitable antagonists of the receptors for this neuropeptide, which it is hoped will have less cardiovascular adverse effects than the triptans. Recently, the initial pharmacological profile of such a group of compounds has been disclosed. These compounds are small molecules with high selectivity for human CGRP receptors. Hypothetically, these agents will be efficacious in the relief of migraine headaches via blockade of the effects of CGRP.
Edvinsson
L
L
Department of Internal Medicine, Lund University Hospital, Lund, Sweden. lars.edvinsson@med.lu.se
D000818:Animals; D015740:Calcitonin Gene-Related Peptide / Q000502:physiology*; D000077221:Calcitonin Gene-Related Peptide Receptor Antagonists; D006261:Headache / Q000188:drug therapy / Q000503:physiopathology* / Q000628:therapy*; D006801:Humans; D018015:Receptors, Calcitonin Gene-Related Peptide / Q000378:metabolism
D000077221:Calcitonin Gene-Related Peptide Receptor Antagonists; D018015:Receptors, Calcitonin Gene-Related Peptide; D015740:Calcitonin Gene-Related Peptide